drugset / Trial / NCT00888732

A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, BIAsp70, BIAsp50 and Fast-acting Human Insulin

NCT00888732

Phase 3 Completed 24 enrolled University of Aarhus Novo Nordisk A/S · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The hypothesis is that an optimal formulation of fast acting and intermediary acting insulin analogues will improve post prandial glycaemic control in patients with type 1 diabetes

Timeline

Start
2009-06
Primary completion
2010-06
Completion
2010-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject BIAsp50 Unknown 0.2 iu/kg Subcutaneous
Subject Insulin Protein / enzyme biologic 0.2 iu/kg Subcutaneous
Subject insulin aspart Protein / enzyme biologic 0.2 iu/kg Subcutaneous